XXXX at Groote Schuur Hospital, 1973-1984.

@entity1 @entity5 @entity900 @entity1442 @entity3 @entity4797
The clinical records of 47 @entity1 with @entity4797 treated between 1973 and 1984 were reviewed. The mean age was 41 years. There were relatively few blacks and @entity1 of mixed race--4% and 17% respectively. The incidence of associated testicular maldescent was statistically significantly higher among the black and mixed-race @entity1 (40%) than among the white @entity1 (8%). Forty-three @entity1 underwent retroperitoneal irradiation after orchidectomy, with a 5-year survival rate of 87% at a median follow-up of 52 months. There were no relapses at follow-up in 27 stage I @entity1 ; 1 of 8 @entity1 with stage IIA and B (non-bulky) disease relapsed after 12 years, and relapses occurred in all 5 @entity1 with stage IIC (bulky) @entity4797 . Retroperitoneal and mediastinal irradiation has controlled disease in 2 @entity1 with @entity5 without bulky @entity3 . One @entity1 with stage IV @entity4797 treated with irradiation relapsed. One of the @entity1 with stage I disease has developed a major bowel complication following 3,000 cGy fractionated irradiation. Our experience with @entity900 -based chemotherapy includes noting its effectiveness in a @entity1 with unresectable locally advanced @entity4797 . We recommend retroperitoneal irradiation after orchidectomy for @entity1 with stage I and IIA/B disease and @entity900 combination chemotherapy after orchidectomy for those with more @entity1442 .
